Demonstrated efficacy profile1

Adult Patients

99% (152/154) of adults had their glucose levels raised to safe levels across 2 clinical trials1,*

*Blood glucose >70 mg/dL or an increase of blood glucose of ≥20 mg/dL from baseline.

Gvoke was evaluated in adult patients aged 18 to 74 years with type 1 diabetes in 2 multicenter, randomized, blinded, 2-way crossover clinical trials. 154 subects received an injection of Gvoke and 157 subjects received an injection of Glucagon Emergency Kit; 152 subjects received both products. The comparison between groups met the prespecified noninferiority margin.

Reference: 1. Gvoke [prescribing information]. Chicago, IL: Xeris Pharmaceuticals, Inc.

100% (30/30) of pediatric patients had their glucose levels raised to safe levels1,†

Average change in plasma glucose at 30 minutes
2‐5 years
(0.5 mg/0.1 mL dose)
6‐11 years
(0.5 mg/0.1 mL dose)
12-17 years
(0.5 mg/0.1 mL dose)
12-17 years
(1 mg/0.2 mL dose)
+81 mg/dL +84 mg/dL +53 mg/dL +55 mg/dL

Target glucose increase of ≥25 mg/dL at 30 minutes.

Gvoke was evaluated in a clinical trial in 31 pediatric patients with type 1 diabetes. Patients were administered insulin to induce a low normal glycemic state of <80mg/dL. Patients aged 2 to <12 years then received a 0.5 mg dose of Gvoke. Patients aged ≥12 years received a 0.5 mg or 1.0 mg dose of Gvoke.

Reference: 1. Gvoke [prescribing information]. Chicago, IL: Xeris Pharmaceuticals, Inc.

99% (152/154) of adults had their glucose levels raised to safe levels across 2 clinical trials1,*

*Blood glucose >70 mg/dL or an increase of blood glucose of ≥20 mg/dL from baseline.

Gvoke was evaluated in adult patients aged 18 to 74 years with type 1 diabetes in 2 multicenter, randomized, blinded, 2-way crossover clinical trials. 154 subects received an injection of Gvoke and 157 subjects received an injection of Glucagon Emergency Kit; 152 subjects received both products. The comparison between groups met the prespecified noninferiority margin.

Pediatric Patients

100% (30/30) of pediatric patients had their glucose levels raise to safe levels†,1

Average change in
plasma glucose at
30 minutes
+81 mg/dL

2-5 years
(0.5 mg/0.1 mL dose)

+84 mg/dL

6-11 years
(0.5 mg/0.1 mL dose)

+53 mg/dL

12-17 years
(0.5 mg/0.1 mL dose)

+55 mg/dL

12-17 years
(1 mg/0.2 mL dose)

†Target glucose increase of ≥25 mg/dL at 30 minutes.

Gvoke was evaluated in a clinical trial in 31 pediatric patients with type 1 diabetes. Patients were administered insulin to induce a low normal glycemic state of <80mg/dL. patients aged 2 to <12 years then received a 0.5 mg dose of Gvoke. Patients aged ≥12 years received a 0.5 mg or 1.0 mg dose of Gvoke.

Reference: 1. Gvoke [prescribing information]. Chicago, IL: Xeris Pharmaceuticals, Inc.